Land: Malta
Språk: engelsk
Kilde: Medicines Authority
TETANUS TOXOID, DIPHTHERIA TOXOID, HAEMOPHILUS TYPE, B POLYSACCHARIDE, POLYRIBOSYLRIBITOL PHOSPHATE, CONJUGATED TO, AS CARRIER, PROTEIN, BORDETELLA PERTUSSIS
Sanofi Pasteur 14 Espace Henry Vallée , 69007 Lyon, France
J07AG52
DIPHTHERIA TOXOID HAEMOPHILUS TYPE B POLYSACCHARIDE (POLYRIBOSYLRIBITOL PHOSPHATE) CONJUGATED TO TETANUS TOXOID AS CARRIER PROTEIN 10 µg BORDETELLA PERTUSSIS 4 IU TETANUS TOXOID 60 IU
POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION
DIPHTHERIA TOXOID HAEMOPHILUS TYPE B POLYSACCHARIDE (POLYRIBOSYLRIBITOL PHOSPHATE) CONJUGATED TO TETANUS TOXOID AS CARRIER PROTEIN 10 µg BORDETELLA PERTUSSIS 4 IU TETANUS TOXOID 60 IU
POM
VACCINES
Withdrawn
2007-01-18
STORAGE Do not exceed the expiry date stated on the external packaging. SPECIAL PRECAUTIONS FOR STORAGE Store at a temperature between + 2°C and + 8°C (in a refrigerator). Do not freeze. Rev. 09-2000 TETRACT-HIB (ACT-HIB - D.T. COQ/D.T.P.) VACUNA DIFTÉRICA, TETÁNICA, PERTÚSICA ADSORBIDA Y HAEMOPHILUS TIPO B CONJUGADA COMPOSICIÓN ACT-HIB (POLVO PARA 1 DOSIS VACUNANTE) : – Polisacárido de _Haemophilus influenzae _tipo b conjugado con la proteína tetánica . . . . 10 µg – Sacarosa y trometamol D.T.COQ/D.T.P. (SUSPENSIÓN INYECTABLE PARA 1 DOSIS VACUNANTE (0,5 ML)) : – toxoide diftérico purificado . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . mínimo 30 U.I. – toxoide tetánico purificado . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . mínimo 60 U.I. _– Bordetella pertussis _. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . mínimo 4 U.I. – Hidróxido de aluminio, mercurotiolato sódico y solución tampón conteniendo cloruro de sodio, hidrógenofosfato de sodio dihidratado, dihidrógenofosfato de potasio, ácido acético y/o hidróxido de sodio y agua para preparaciones inyectables. FORMA FARMACÉUTICA PRESENTACIÓN DOSIS ÚNICA : Suspensión inyectable obtenida por reconstitución del polvo de un frasco de Act-HIB mediante una jeringa o ampolla (0,5 ml) de D.T.COQ/D.T.P. PRESENTACIÓN MULTIDOSIS : Suspensión inyectable obtenida por reconstitución del polvo de un frasco de 10 dosis de Act-HIB mediante un frasco de 10 dosis de 0,5 ml de D.T.COQ/D.T.P. TITULAR DE LA AUTORIZACIÓN DE PUESTA EN EL MERCADO SANOFI PASTEUR SA 2, avenue Pont Pasteur, 69007 Lyon - France INDICACIONES Este medicamento es una VACUNA. Esta vacuna combinada está indicada en la prevención conjunta de infecciones inv Les hele dokumentet
Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TETRACT-HIB, powder and suspension for injection for suspension for injection in prefilled syringe, adsorbed diphtheria, tetanus, pertussis and _Haemophilus_ type b conjugate vaccine. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Chamber containing the powder: _Haemophilus influenzae_ type b polysaccharide conjugated to tetanus protein 10 µg Adsorbed diphtheria toxoid 30 IU Adsorbed tetanus toxoid 60 IU Adsorbed _Bordetella pertussis_ 4 IU for one 0.5 ml dose after reconstitution 3. PHARMACEUTICAL FORM Powder and suspension for suspension for injection in a prefilled syringe. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS This combined vaccine is indicated for the joint prevention of invasive _Haemophilus influenzae_ type b infections (meningitis, septicaemia, cellulitis, arthritis, epiglottitis…), diphtheria, tetanus and pertussis. The vaccine does not protect against infections due to other types of _Haemophilus influenzae_, or against meningitis of other origins. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Posology: 3 injections of a unit dose of vaccine (0.5 ml) at one month interval, in compliance with the official immunization schedule, one injection at the age of 2, 3 and 4 months followed by a booster injection : one injection a year after primary immunization. Method of administration: Given that this vaccine is adsorbed, it is preferable to administer it by the intramuscular route in order to minimize local reactions. The vaccine is preferably administered in the anterolateral side of the thigh (middle third). Do not inject by the intravascular route. The vaccine should be administered after reconstitution of the powder contained in the vial using the suspension contained in the prefilled syringe. P Les hele dokumentet